LLY
Eli Lilly and Company
LLY has the edge over NXL overall, supported by lower modeled downside and stronger fundamentals.
NXL
Nexalin Technology, Inc.
NXL's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
NXL Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
NXL's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
NXL PE Valuation
NXL has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
NXL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| -- | |
| Limited | |
| High |
Analysts expect NXL's losses to shrink, with revenue growing.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over NXL on earnings quality, reporting a profit while its opponent remains loss making.
NXL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.63 | +$6.47 |
| Q2 2026 | -$14.10 | +$9.00 |
| Q1 2026 | -$13.80 | +$11.40 |
| Q4 2025 | -$15.00 | +$9.90 |
| Q3 2025 | -$20.10 | -$0.68 |
| Q2 2025 | -$23.10 | -$1.28 |
| Q1 2025 | -$25.20 | -$5.18 |
| Q4 2024 | -$24.90 | -$6.00 |
NXL is still losing money, but far less than before: $13.63 per share over the past year, against $34.20 at its worst in late 2021.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over NXL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over NXL on profitability, with a higher operating margin.
NXL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $78.3K | +331% |
| Q2 2026 | $12.2K | -83% |
| Q1 2026 | $15K | -64% |
| Q4 2025 | $171.9K | +532% |
| Q3 2025 | $18.1K | -50% |
| Q2 2025 | $70.6K | +163% |
| Q1 2025 | $41K | -48% |
| Q4 2024 | $27.2K | +32% |
NXL's revenue is recovering but still below its 2022 peak: $78,301 last quarter, up 331% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3332% | +9592 points |
| Q2 2026 | -18480% | -16184 points |
| Q1 2026 | -14180% | -9276 points |
| Q4 2025 | -1404% | +9176 points |
| Q3 2025 | -12924% | -5962 points |
| Q2 2025 | -2296% | +2536 points |
| Q1 2025 | -4904% | -3539 points |
| Q4 2024 | -10579% | -2669 points |
NXL's operating margin was −3332% last quarter, up 9592 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over NXL on cash generation, producing positive trailing cash flow while its opponent burns cash.
NXL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.6M | -$121.5K |
| Q2 2026 | -$1.8M | -$884.5K |
| Q1 2026 | -$1.7M | -$286.8K |
| Q4 2025 | -$1.1M | -$13.5K |
| Q3 2025 | -$1.5M | -$666K |
| Q2 2025 | -$917.2K | +$329.3K |
| Q1 2025 | -$1.4M | -$662.9K |
| Q4 2024 | -$1.1M | -$130.4K |
NXL has burned cash in almost every quarter: −$6M over the past year, against −$5M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over NXL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
NXL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +10% | +71.9K shares |
| 1 year | +48% | +253K shares |
| 3 years | +220% | +534K shares |
| 5 years | +376% | +613K shares |
NXL has 776,657 diluted shares, up 48% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
NXL Net Leverage
NXL's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
NXL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.1 | Oversold |
| Stochastic | 1.3 | Oversold |
NXL's weekly RSI is 29 (oversold) and its Stochastic is 1 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
NXL PE vs Healthcare Sector
NXL has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over NXL on trend strength, trading above more of its moving averages.
NXL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.81 | 47% below |
| 20 week MA | $6.97 | 79% below |
| 50 week MA | $12.1 | 88% below |
| 100 week MA | $31.0 | 95% below |
| 200 week MA | $31.2 | 95% below |
NXL is in a downtrend: it's below all five of its weekly moving averages, and 95% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over NXL on returns for 2026, with the stronger performance.
NXL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $67.5 | $23.4 | -65% |
| 2023 | $23.4 | $12.1 | -48% |
| 2024 | $12.1 | $88.5 | +629% |
| 2025 | $88.5 | $18.9 | -79% |
| 2026 YTD | $18.9 | $1.49 | -92% |
NXL's yearly returns have swung widely, from +629% in 2024 to −79% in 2025. It's down 92% so far in 2026.